Literature DB >> 3955451

Prevalence of multiple sclerosis in British Columbia.

V P Sweeney, A D Sadovnick, V Brandejs.   

Abstract

A province wide prevalence study on multiple sclerosis (MS) was conducted in British Columbia (B.C.). The prevalence date was July 1, 1982. The major portion of this study was a review of all the files of neurologists practicing in B.C. as this was judged to be the most accurate source for identifying MS patients. 239,412 neurologists' files were hand searched by one researcher using modified Schumacher criteria for classification. Other sources used during the study for identifying MS patients were the MS Clinic, general practitioners, ophthalmologists, urologists, specialized facilities such as long term care facilities and rehabilitation centres, and patient self-referrals. A total of 4,620 non-duplicated cases were identified and classified. 4,112 of these (89%) were classified according to information contained in neurologists' records. The prevalence estimate for definite/probable MS in B.C. was 93.3/100,000 population. This increased to 130.5/100,000 population if possible MS and optic neuritis were also included. These rates are among the highest reported in Canada or elsewhere. The cooperation of B.C. neurologists made this study unique in its scope and accuracy of diagnosis.

Entities:  

Mesh:

Year:  1986        PMID: 3955451     DOI: 10.1017/s0317167100035782

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  14 in total

1.  Impact of multiple sclerosis relapses on progression diminishes with time.

Authors:  H Tremlett; M Yousefi; V Devonshire; P Rieckmann; Y Zhao
Journal:  Neurology       Date:  2009-11-04       Impact factor: 9.910

Review 2.  The inheritance of MS susceptibility.

Authors:  D Lord; A G O'Farrell; H Staunton; E Keelan
Journal:  Ir J Med Sci       Date:  1990-01       Impact factor: 1.568

3.  Risks of multiple sclerosis in relatives of patients in Flanders, Belgium.

Authors:  H Carton; R Vlietinck; J Debruyne; J De Keyser; M B D'Hooghe; R Loos; R Medaer; L Truyen; I M Yee; A D Sadovnick
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

4.  Obstetrical epidural and spinal anesthesia in multiple sclerosis.

Authors:  Ellen Lu; Yinshan Zhao; Leanne Dahlgren; Roanne Preston; Mia van der Kop; Anne Synnes; A Dessa Sadovnick; Anthony Traboulsee; Helen Tremlett
Journal:  J Neurol       Date:  2013-07-18       Impact factor: 4.849

Review 5.  Epidemiologic evidence for multiple sclerosis as an infection.

Authors:  J F Kurtzke
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

6.  Birth hospitalization in mothers with multiple sclerosis and their newborns.

Authors:  Ellen Lu; Yinshan Zhao; Feng Zhu; Mia L van der Kop; Anne Synnes; Leanne Dahlgren; A Dessa Sadovnick; Ana-Luiza Sayao; Helen Tremlett
Journal:  Neurology       Date:  2013-01-09       Impact factor: 9.910

7.  Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs.

Authors:  Ellen Lu; Feng Zhu; Yinshan Zhao; Mia van der Kop; Anne Synnes; Leanne Dahlgren; A Dessa Sadovnick; Anthony Traboulsee; Helen Tremlett
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

8.  Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities.

Authors:  Helen Tremlett; Yinshan Zhao; Virginia Devonshire
Journal:  J Neurol       Date:  2009-03-18       Impact factor: 4.849

9.  Geomagnetic disturbances may be environmental risk factor for multiple sclerosis: an ecological study of 111 locations in 24 countries.

Authors:  Seyed Aidin Sajedi; Fahimeh Abdollahi
Journal:  BMC Neurol       Date:  2012-09-24       Impact factor: 2.474

10.  Neonatal and delivery outcomes in women with multiple sclerosis.

Authors:  Mia L van der Kop; Mark S Pearce; Leanne Dahlgren; Anne Synnes; Dessa Sadovnick; Ana-Luiza Sayao; Helen Tremlett
Journal:  Ann Neurol       Date:  2011-06-27       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.